Downloads

Epistem provides a suite of analytical services which can be utilised as an integrated component of an in-house study package or as a stand-alone service.

Epistem provides global (microarray) and focused (qPCR) GCLP accredited mRNA and miRNA gene expression profiling services. Expression profiles can be generated from pg-μg levels of RNA permitting analysis of small starting materials

Epistem’s proprietary amplification technique, RNA-Amp™, allows robust gene expression information to be derived from as little as a single cell input.

Epistem RNA-Amp™ amplification kits are extremely sensitive and user friendly. Our kits use a proprietary combination of components to amplify cDNA prepared from small amounts of tissue and RNA.

Epistem provides laboratory GCLP (microarray and qPCR) and point of care (Genedrive®) ISO 13485 accredited DNA genotyping services.

Epistem has world recognised intestinal and oral mucositis expertise, providing industry standard models predictive of clinical outcome.

Epistem provides specialist epithelial tissue and stem cell analysis to investigate the aetiology, mechanism and prevention of epithelial toxicity.

Epistem has been continuously providing GI services since its foundation in 2000. Epistem has world recognised GI expertise that can help predict, identify the cause and devise possible mitigation strategies for GI toxicity.

Epistem has provided services to NIAID, BARDA, DoD and AFRRI to evaluate potential radioprotectors and mitigators of interest to the US national stockpile. The models are run in accordance with the FDA “Animal Rule".

Epistem provides a tailored histology and immunohistochemistry service to assist with the validation of novel therapeutic targets, either as part of an integrated package or as a stand-alone service. The service is delivered by experienced histologists

Epistem’s inflammation experts provide a range of specialised preclinical models to support target validation and drug development for inflammatory diseases.

High quality preclinical data from a range of in vivo IBD models and target validation studies to aid the development of new anti-inflammatory therapies.

Epistem offers Laser Capture Microdissection (LCM) services and subsequent gene expression and DNA genotype analysis. This technique is an ideal method for obtaining molecular analysis of specific cell populations. Following the isolation of cells of i

Epistem has world recognised intestinal and oral mucositis expertise, providing industry standard models predictive of clinical outcome.

Epistem provides specialist epithelial tissue and stem cell analysis to investigate the aetiology, mechanism and prevention of epithelial toxicity.

Epistem has been continuously providing GI services since its foundation in 2000. Epistem has world recognised GI expertise that can help predict, identify the cause and devise possible mitigation strategies for GI toxicity.

Epistem has provided services to NIAID, BARDA, DoD and AFRRI to evaluate potential radioprotectors and mitigators of interest to the US national stockpile. The models are run in accordance with the FDA “Animal Rule".

In Vitro and In Vivo Human Angiogenesis Assays

Epistem offers tumour sphere assays as part of a comprehensive preclinical oncology programme, from initial assessment of target gene or protein expression to evaluation of cancer stem cell targeting efficacy in vitro.

Epistem provides clinically relevant in vivo models of leukemia using both patient-derived material and established cell line models. Luciferase imaging enables early detection of leukemia, allowing for an extended treatment window and longitudinal mo

Epistem provides clinically relevant orthotopic in vivo models of solid and metastatic tumors, using highly sensitive state-of-the-art optical imaging with luc+ cell lines, enabling real time visualization of therapeutic outcomes.

Epistem provides specialist subcutaneous xenografting services covering a comprehensive range of in vivo epithelial tumour models. Specialist radiation and chemotherapy combination models, and complementary assessment of target and biomarker ...

Epistem provides a unique plucked hair biomarker platform to drug development companies targeting intracellular signalling pathways in oncology and other therapeutic areas. Plucked hair analysis offers a simple to apply and minimally invasive techniqu

Plucked hair is an attractive non-invasive surrogate tissue to aid drug development programs, particularly with respect to phamacodynamic biomarker discovery and clinical applications. With low intra- and inter-donor variation key to successful utility

Epistem provides specialist subcutaneous xenografting services covering a comprehensive range of in vivo epithelial tumour models. Specialist radiation and chemotherapy combination models, and complementary assessment of target and biomarker ...

Epistem provides a range of specialist in vitro models of human skin to cosmetic, personal care and pharmaceutical companies for claims and patent support, biomarker proof of concept and efficacy testing.

Epistem provides specialist subcutaneous xenografting services covering a comprehensive range of in vivo epithelial tumour models. Specialist radiation and chemotherapy combination models, and complementary assessment of target and biomarker ...

Epistem provides a range of in vitro and in vivo models to assess the complex processes involved in wound healing and to determine the effect of agents on healing rate.

Epistem provides a range of in vitro and in vivo models to assess the complex processes involved in wound healing and to determine the effect of agents on healing rate.

Epistem has been continuously providing GI services since its foundation in 2000. Validated multi-species in vitro 3D model of normal intestinal tissue. Useful to investigate drug induced epithelial toxicity and regeneration.

We have developed a reproducible, well growing and robust subcutaneous model of LNCaP with an effective response to both conventional standard of care (SOC) chemotherapy such as docetaxel and the non-steroidal androgen receptor inhibitor bicalutamide (Casodex).

Ex vivo plucked hair assessment generated a dose-dependent and biologically relevant transcriptional signature following exposure to BEZ235, and substantiate that plucked anagen scalp hair is an ideal non-invasive surrogate tissue to obtain drug-induced pharmacodynamic biomarker and target engagement information from oncology patients.